Novartis AG (NYSE:NVS) on Friday agreed to acquire a next-generation PI3Kα inhibitor program from Synnovation Therapeutics, aiming to strengthen its breast cancer pipeline with a more targeted and potentially better-tolerated treatment approach.

• Novartis stock is taking a breather. What should traders watch with NVS?

Novartis Targets Next-Generation Breast Cancer Therapy

The deal centers on SNV4818, an oral, pan-mutant–selective PI3Kα inhibitor currently in Phase 1/2 trials for breast cancer and other advanced solid tumors.

The therapy is designed for patients with HR-positive, HER2-negative breast cancer, a segment where roughly 40% of patients harbor PIK3CA mutations linked to poorer outcomes.

The acquisition aligns with Novartis' broader oncology strategy to develop precision medicines that can be combined with existing treatments, including CDK inhibitors and endocrine therapies, to improve